FemTech Fundraising: Active VCs & Women's Health Playbook

How to raise venture capital for a femtech, women's health, fertility, menopause, or maternal-health startup in 2026.

How to Raise Venture Capital for a FemTech Startup

FemTech and women's health — Maven Clinic, Kindbody, Progyny, Tia, Elvie, Flo Health, Clue, Natural Cycles, Modern Fertility (Ro), Peppy, Evernow, Midi Health, Alloy, plus fertility clinic networks and maternal-health platforms — spans fertility, menopause, maternal health, contraception, pelvic health, and general women's-health navigation.

Why femtech is a distinct fundraising category

Femtech investors underwrite FDA regulatory pathways (De Novo, 510(k), PMA for devices; wellness vs medical claims for apps), clinical evidence (RCTs for fertility / menopause / maternal health), payer coverage (commercial + Medicaid state-by-state), employer-benefit sales cycles (12–18 months for Fortune 500 with benefits consultants like Mercer, Aon, WTW), and D2C CAC realities in a category where sensitive personal data drives higher trust bar.

The most active femtech VCs

FemTech / women's health focused: Astarte Ventures, Amboy Street Ventures, Portfolia FemTech Fund, Female Founders Fund, Coyote Ventures, RH Capital, Steel Sky Ventures, Avestria Ventures, and BBG Ventures.

Multi-stage generalists active in femtech: a16z Bio + Health, GV, Founders Fund, Sequoia, General Catalyst, Oak HC/FT, 7wireVentures, F-Prime, Bessemer, Lux, and Khosla.

Strategic capital: Organon, Bayer G4A, J&J JLABS, Merck GHI Fund, Roche + Genentech, Novo Ventures, Optum Ventures, CVS Health Ventures, Anthem / Elevance Health, Humana Studio H, plus employer-benefit strategics.

FDA / clinical realities

Medical devices (Elvie's pump, Willow, Bloomlife, Owlet, Bloomer Tech, Nyquist Data) follow standard FDA pathways: 510(k) for substantial equivalence, De Novo for novel low-to-moderate risk, PMA for Class III (rare). Timelines 12–36 months, cost $500K–$5M.

Cycle-tracking / fertility apps face the wellness-vs-medical-device line. Natural Cycles' De Novo clearance (2018) as contraception was category-defining. Clue, Flo, Ovia typically stay wellness with clinical publications rather than FDA clearance.

Menopause / hormonal treatments (Evernow, Midi Health, Alloy) require state medical licensing, controlled-substance handling (some HRT), and telemedicine compliance state-by-state (Ryan Haight Act, state DEA rules).

Payer coverage and employer benefits

Commercial payer coverage for fertility (IVF, egg freezing) is expanding but state-mandated in only ~20 states. Progyny's carve-out benefit model unlocked Fortune 500 coverage. Maven, Kindbody, Peppy, Midi, Alloy sell primarily to employer benefits (12–18 month sales cycles via Mercer, Aon, WTW consultants). Menopause coverage is early — inclusion in Fortune 500 benefits (Bank of America, Adobe, Microsoft, Salesforce) was a 2023–2025 breakthrough.

D2C vs employer-benefit go-to-market

D2C femtech (Modern Fertility, Elvie, Flo, Clue, Rory / Ro) faces $150–$500 CAC with sensitive-category paid-media restrictions (Meta / Google flag women's-health ads for review). Employer-benefit (Maven, Kindbody, Progyny, Peppy, Midi Health) has longer sales cycles but 3–5x higher ARPU, near-zero individual CAC, and lower churn (employer contract renewals). Hybrid models (Ro's Modern Fertility + Ro D2C) are increasingly common.

Common mistakes when raising for femtech

Naming 'employer clients' without signed contracts. Underestimating FDA pathway timelines for medical devices. Blurring wellness-vs-medical-device claims (SEC / FDA / FTC risk). Ignoring state-by-state telemedicine compliance for hormonal treatments. D2C-only strategy when employer benefits are the higher-quality revenue. Underestimating sensitive-category paid-media restrictions. Not disclosing pregnancy-loss / abortion data handling post-Dobbs (major diligence concern for consumer trust and regulatory risk).

Frequently asked questions

Which are the most active femtech VCs in 2026?
Astarte Ventures, Amboy Street Ventures, Portfolia FemTech Fund, Female Founders Fund, Coyote Ventures, RH Capital, Steel Sky Ventures, Avestria Ventures, and BBG Ventures lead the dedicated set. Generalists Andreessen Horowitz Bio + Health, GV, Founders Fund, Sequoia, General Catalyst, Oak HC/FT, 7wireVentures, F-Prime, Bessemer, Lux, and Khosla are active. Strategic capital from Organon, Bayer G4A, J&J JLABS, Merck GHI Fund, Roche + Genentech, Novo Ventures, Optum Ventures, CVS Health Ventures, Anthem / Elevance Health, and Humana Studio H.
Do femtech medical devices need FDA clearance?
Yes, medical devices follow standard FDA pathways: 510(k) for substantial equivalence, De Novo for novel low-to-moderate risk, PMA for Class III. Timelines run 12–36 months with $500K–$5M in cost. Cycle-tracking / fertility apps face the wellness-vs-medical-device line — Natural Cycles' De Novo clearance in 2018 as contraception was category-defining; Clue, Flo, and Ovia typically stay wellness with clinical publications rather than FDA clearance.
How long are employer-benefit sales cycles for femtech?
Employer-benefit sales cycles run 12–18 months for Fortune 500, gated by benefits consultants (Mercer, Aon, WTW) and HR / Benefits committee approval. Maven Clinic, Kindbody, Progyny, Peppy, and Midi Health run this playbook. ARPU is 3–5x higher than D2C with near-zero individual CAC and lower churn (employer contract renewals).
How has post-Dobbs data handling changed femtech diligence?
Pregnancy-loss / abortion / cycle data handling post-Dobbs (2022) is now a major diligence concern for consumer trust and regulatory risk. Investors expect data minimization, on-device storage where possible, jurisdictional strategy (data residency in privacy-friendly states / countries), and a clear law-enforcement request policy. Companies without a defensible post-Dobbs data posture face material diligence friction.
What are realistic D2C CACs for femtech in a restricted-ad category?
$150–$500 CAC is typical. Meta and Google flag women's-health ads for review under sensitive-category paid-media restrictions, so paid social is constrained. SEO + creator partnerships + physician / clinic partnerships + employer channels often outperform paid social on payback. Retention is critical because CAC is high — 18-month payback is a strong band.

Related fundraising verticals (40)

Investor directory · Fundraising library · Articles A–Z · Company funding database